U.S. Markets closed

Cytori Therapeutics, Inc. (CYTX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.030.00 (0.00%)
At close: 4:00PM EDT
People also watch
OSIRATHXCURCYCCOPXA
Interactive chart
Previous Close1.03
Open1.04
Bid0.98 x 3000
Ask1.08 x 1000
Day's Range1.01 - 1.04
52 Week Range0.90 - 2.96
Volume165,792
Avg. Volume770,479
Market Cap33.45M
Beta2.86
PE Ratio (TTM)-0.84
EPS (TTM)-1.23
Earnings DateMar 3, 2017 - Mar 6, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.10
Trade prices are not sourced from all markets
  • Capital Cube4 days ago

    ETFs with exposure to Cytori Therapeutics, Inc. : May 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cytori Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CYTX-US. Comparing the performance and risk of Cytori Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
    Capital Cube5 days ago

    Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Cytori Therapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Cytori Therapeutics, Inc. – Athersys, Inc., Baxter International Inc., Retractable Technologies, Inc., Vericel Corporation, Haemonetics Corporation, CryoLife, Inc., Cesca Therapeutics Inc., Caladrius Biosciences, Inc. and Cerus Corporation (ATHX-US, ... Read more (Read more...)

  • GlobeNewswire6 days ago

    Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial

    SAN DIEGO, Calif., May 23, 2017-- Cytori Therapeutics, Inc., today announced that it has now completed all 48 week follow up monitoring visits in its U.S. FDA approved Phase III STAR trial. A total of ...